Eisai Company Limited reported mixed financial results for Q4 of fiscal year 2025, ending March 31, 2026. The company achieved a record-high revenue of JPY 825.4 billion, a 4.6% year-on-year increase, but operating profit fell by 18.8% to JPY 44.1 billion. Net profit also decreased by 17% to JPY 38.6 billion.
Revenue growth was driven by strong performance in the pharmaceutical segment, particularly the “3L products”: LEQEMBI, DAYVIGO, and LENVIMA. However, profit declines were attributed to strategic decisions to forgo out-licensing and unexpected restructuring costs in Europe.
According to Bond.az analysis, the stock saw a slight increase of 0.04%, but the company appears undervalued. For FY 2026, Eisai projects revenue of JPY 883.5 billion and operating profit of JPY 70 billion.
